ProEncia Biotechnology announced it has closed a significant pre-seed funding round to accelerate development of its next-generation periodontal disease treatment pipeline.
The funding will be used to further develop, commercialize, and license a portfolio of novel, non-invasive periodontal care products designed for patients across all stages of periodontal disease severity. The company is focused on creating easy-to-use, non-toxic oral care solutions targeting conditions including gingivitis and periodontitis.
ProEncia also announced that the United States Patent and Trademark Office confirmed its provisional patent application, titled “Compositions and Method for Prophylactic, Symptomatic, Therapeutic, and Cosmetic Periodontal Care,” has been incorporated into a non-provisional PCT International application and entered into the federal patent filing system.
According to the company, periodontal disease affects more than one billion people globally and over 100 million people in the United States, highlighting the scale of the oral health market opportunity and the need for additional treatment innovation.
Founded in 2022, ProEncia Biotechnology was co-founded with scientific and clinical leadership from Dr. Tarun Ghosh and Dr. Thomas Hoover. The company is developing multiple prophylactic and therapeutic products based on its patent-pending periodontal treatment technology.
KEY QUOTES:
“According to the World Health Organization, more than one billion people globally, and more than 100 million people in the U.S., suffer from periodontal disease. There’s an urgent need for innovation to resolve this epidemic and bring safe, effective solutions to lifelong sufferers of this condition.”
Tapos Ghosh, CEO And Co-Founder, ProEncia Biotechnology
“The commercial demand for a new approach to periodontal treatment is enormous. The ProEncia team is committed to advancing its groundbreaking treatment and expanding care options for periodontal disease patients.”
Austin Loeb, COO And Co-Founder, ProEncia Biotechnology
